{"id":"tp-37465","type":"article-newspaper","title":"European Commission Expands Keytruda-Padcev Use for Cisplatin-Eligible MIBC","author":"Riza Dagoc","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/regulation/37465","datePublished":"2026-10-22T04:37:03.000Z","dateModified":"2026-10-22T04:37:03.000Z","language":"en","abstract":"A Phase 3 trial found 24-month event-free survival of 79.4% with the combination, versus 66.2% with gemcitabine-cisplatin.","section":"Regulation","references":[]}